Perseus Proteomics Inc. (4882)
JPX JPX Primary Summary
Perseus Proteomics Inc. (4882) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Perseus Proteomics Inc. ever had a stock split?
Perseus Proteomics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Takuya Yokokawa CEO | JPX Exchange | JP3836800007 ISIN |
| Japan Country | 32 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Perseus Proteomics Inc. operates as a drug discovery biotechnology venture focused on the development of antibody drugs targeting cancer and various other diseases. Based in Tokyo, Japan, this company is involved in several key activities within the biotech industry, including antibody discovery and a range of research support services. These services encompass hybridoma antibody sequencing, antibody protein production, and contract-based antibody research, in addition to the provision of antibody products. Established in 2001, Perseus Proteomics Inc. has concentrated its efforts on harnessing the therapeutic potential of antibodies to address critical medical needs.
Products and Services
-
PPMX-T001 (Anti-Hepatocarcinoma Antibody)
This product is an antibody treatment devised to combat hepatocellular carcinoma, which is the most common type of liver cancer. As one of the company's leading pipeline drugs, PPMX-T001 represents Perseus Proteomics Inc.'s commitment to fighting cancer through innovative biotechnological solutions.
-
PPMX-T002 (Anticancer Drug)
PPMX-T002 is described as an anticancer drug, with its specific target and mechanism promising to offer new treatment possibilities for cancer patients. Though details on its action and target cancers are scant, its place in the pipeline underscores the company's broader focus on oncology.
-
PPMX-T003 (Drug for the Treatment of Adult T-cell)
This drug is designed for treating adult T-cell leukemia/lymphoma, a rare and often aggressive form of cancer that affects the T-cells, a type of lymphocyte. PPMX-T003's development reflects the company's dedication to addressing less common but significantly impactful diseases.
-
PPMX-T004 (Antibody Drug Conjugate)
An innovative approach combining an antibody with a chemotherapy drug, PPMX-T004 is intended to specifically target and kill cancer cells while sparing healthy cells. As an antibody-drug conjugate, it represents a fusion of targeted therapy and conventional chemotherapy principles, potentially offering enhanced efficacy with reduced side effects.
